Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan N Barker

Showing results (31-40 of 104) with videos related to

Pageof 11
Sort By:
The Journal of Investigative Dermatology|March 8, 2023
Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center ExperienceAntony Raharja, Zehra Arkir, Giulia Rinaldi, et al.
Dermatology and Therapy|April 4, 2025
Correction: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological ConditionsKenneth B Gordon, Yayoi Tada, Milan J Anadkat, et al.
The British Journal of Dermatology|January 23, 2025
Global Delphi consensus on treatment goals for generalized pustular psoriasisJonathan N Barker, Emmylou Casanova, Siew Eng Choon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 2, 2025
Prevalence of comorbidity amongst people with palmoplantar pustulosis: A systematic review and meta-analysisDavid Gleeson, Mark Corbett, Shern P Choy, et al.
Nature Communications|January 30, 2024
Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockadeLuc Francis, Daniel McCluskey, Clarisse Ganier, et al.
The Journal of Investigative Dermatology|May 7, 2010
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditionsBatya B Davidovici, Naveed Sattar, Jörg C Prinz, et al.
The Journal of Investigative Dermatology|January 30, 2013
Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosisAlexander A Navarini, Laurence Valeyrie-Allanore, Niovi Setta-Kaffetzi, et al.
The Journal of Investigative Dermatology|August 20, 2013
Generalized pustular eruptions: time to adapt the disease taxonomy to the genetic architecture?Alexander A Navarini, Laurence Valeyrie-Allanore, Niovi Setta-Kaffetzi, et al.
The Journal of Investigative Dermatology|November 25, 2011
Allele-specific cytokine responses at the HLA-C locus: implications for psoriasisChristian Hundhausen, Anna Bertoni, Rose K Mak, et al.
Science Translational Medicine|October 13, 2017
An analysis of IL-36 signature genes and individuals with <i>IL1RL2</i> knockout mutations validates IL-36 as a psoriasis therapeutic targetSatveer K Mahil, Marika Catapano, Paola Di Meglio, et al.
Pageof 11

Showing results (31-40 of 104) with videos related to

Sort By:
Pageof 11
The Journal of Investigative Dermatology|March 8, 2023
Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center ExperienceAntony Raharja, Zehra Arkir, Giulia Rinaldi, et al.
Dermatology and Therapy|April 4, 2025
Correction: Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological ConditionsKenneth B Gordon, Yayoi Tada, Milan J Anadkat, et al.
The British Journal of Dermatology|January 23, 2025
Global Delphi consensus on treatment goals for generalized pustular psoriasisJonathan N Barker, Emmylou Casanova, Siew Eng Choon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 2, 2025
Prevalence of comorbidity amongst people with palmoplantar pustulosis: A systematic review and meta-analysisDavid Gleeson, Mark Corbett, Shern P Choy, et al.
Nature Communications|January 30, 2024
Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockadeLuc Francis, Daniel McCluskey, Clarisse Ganier, et al.
The Journal of Investigative Dermatology|May 7, 2010
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditionsBatya B Davidovici, Naveed Sattar, Jörg C Prinz, et al.
The Journal of Investigative Dermatology|January 30, 2013
Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosisAlexander A Navarini, Laurence Valeyrie-Allanore, Niovi Setta-Kaffetzi, et al.
The Journal of Investigative Dermatology|August 20, 2013
Generalized pustular eruptions: time to adapt the disease taxonomy to the genetic architecture?Alexander A Navarini, Laurence Valeyrie-Allanore, Niovi Setta-Kaffetzi, et al.
The Journal of Investigative Dermatology|November 25, 2011
Allele-specific cytokine responses at the HLA-C locus: implications for psoriasisChristian Hundhausen, Anna Bertoni, Rose K Mak, et al.
Science Translational Medicine|October 13, 2017
An analysis of IL-36 signature genes and individuals with <i>IL1RL2</i> knockout mutations validates IL-36 as a psoriasis therapeutic targetSatveer K Mahil, Marika Catapano, Paola Di Meglio, et al.
Pageof 11